Omnicare Inc

Omnicare — Q4 2010 Earnings Presentation

19 slides from Omnicare's earnings presentation, Feb 24, 2011

  1. Slide 1: Fourth Quarter and Full Year 2010 Financial Results

    Exhibit 99.2 Fourth Quarter and Full Year 2010 Financial Results Supplemental Slides

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for historical information discussed, the statements made today and listed within the following presentation slides are forward-looking statements that involve risks and uncertainties. Investors are cautioned that such statements are only predictions and that actual

  3. Slide 3: Table of Contents

    Table of Contents Fourth Quarter 2010 Highlights……………………………………………….4 Operating Metrics - Script Data……………………………………………….5 Operating Metrics - Bed Data…………………………………………………6 Adjusted Gross Profit………………...………………………………………...7 Adjusted Net Income……………………………………………………………8 Cash Flows……………………………………………………………………

  4. Slide 4: Fourth Quarter 2010 Highlights

    Fourth Quarter 2010 Highlights • Scripts dispensed increased 2.1% sequentially – Scripts benefitted from a full quarter’s impact of the CCRx acquisition – Utilization relatively even sequentially – Census was lower, although rate of decline improved again sequentially • Qtr. ending number of beds se

  5. Slide 5: Operating Metrics: Script Data

    Operating Metrics Script Data • Scripts up 2.1% sequentially largely due to: • Increase in the avg. number of beds served during the quarter (full quarter benefit of CCRX acquisition) • Growth in average number of beds served was partially offset by slightly lower occupancy rates at customer facilit

  6. Slide 6: Operating Metrics: Bed Data

    Operating Metrics Bed Data • 3.7% sequential improvement in bed losses - improved performance despite initiative to exit more accounts for contractual terms/A/R issues • Additions up 29.4% compared to 4Q09, although lower sequentially due to decline in acquisitions and organic adds • Beds added by a

  7. Slide 7: Adjusted Gross Profit

    Adjusted Gross Profit (1) (1) Each amount is reported independently. The sum of the individual amounts may not equal the sum of the separately presented amounts due to rounding. (2) Excludes discontinued operations. (3) Excludes special items. A reconciliation of non-GAAP information has been attach

  8. Slide 8: Adjusted Net Income

    Adjusted Net Income (1),(2) (3) The 4Q 2010 and 3Q2010 periods have been computed using basic weighted average shares outstanding only, as the impact of the Company’s potentially dilutive instruments was anti-dilutive during the period due to the GAAP net loss incurred. (4) 4Q 2009 results included

  9. Slide 9: Cash Flows

    Cash Flows • Sequential decrease in operating cash flow reflects decrease in adjusted net income, which was partially offset by improvements in working capital (driven by lower accounts receivable balance; DSOs were lower by approximately 4 days sequentially) • 3Q10 Operating cash flow includes appr

  10. Slide 10: Cash Deployment

    Cash Deployment • Full-year 2010 acquisition spend largely driven by CCRX acquisition • 4Q10 dividend of $0.0325 per share • Repurchased an additional 0.8 million shares ($18.2 million) during 4Q10 (4.4 million shares repurchased in 2010) • $99.1 million of authorization remaining under current shar

  11. Slide 11: Capital Structure

    Capital Structure Recent capital restructuring initiatives have extended maturities, providing more flexibility for capital allocation strategies (1) Assumes convertible debentures due 2035 are put to the company in 2015 with related tax capture included. (2) Debt amounts shown exclusive of unamorti

  12. Slide 12: 2011 Drivers

    2011 Drivers Major 2011 Drivers 1st Half 2011 2nd Half 2011 • Brand-to-generic and drug price Positive Positive inflation • Annualized pricing adjustments Negative Neutral • Annualized impact of bed losses Negative Neutral • Impact of payroll costs Negative Negative • Productivity improvements Posit

  13. Slide 13: 2011 Guidance

    2011 Guidance 2011 Guidance 2010 Results (1) % Change • Revenues $6.1B $6.0B to $6.1B -1.6% to 0.0% • Adjusted EPS (2) $2.10 $2.05 to $2.15 -2.4% to 2.4% • Cash Flow from Operations (3) $369.3M $375M to $425M 1.5% to 15.1% (1) Guidance provided on February 24, 2011. (2) Excludes special items and di

  14. Slide 14: Longer-Term Targets

    Longer-Term Targets (1) Target Double digit three-year CAGR • Adjusted EPS for the year ending 2013 • Cash Flow from Operations $450 million annually • Capital Returned to Shareholders Approximately 25% per year (2) Focus on continued debt reduction, • Capital Structure management of maturity schedu

  15. Slide 15: Appendix

    Appendix 15

  16. Slide 16: Working Capital Management

    Working Capital Management Two-Year Trend # of Days # of Days (1 ) 16

  17. Slide 17: Selected Branded Drug Patent Expirations

    Selected Branded Drug Patent Expirations (1),(2) 4Q 2010 1Q 2011 FY 2011 Accolate Lotrel Aromasin Ambien CR Rythymol SR Concerta Aricept IR Vfend Fazaclo Prevacid Soltabs Tricor Femara Tussionex Xalatan Gabitril Zyzal Levaquin Lipitor Nasacort AQ Uroxatrol Zyprexa (1) All generic launches are subjec

  18. Slide 18: Fourth Quarter and Full Year 2010 Financial Results

    Fourth Quarter and Full Year 2010 Financial Results Supplemental Slides

  19. Slide 19: Slide 19

Omnicare — Q4 2010 Earnings Presentation on 6ix